Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

GILEAD SCIENCES, INC.

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 21, 2025
Income
$60,000.00
Expenses
Not reported
Filing UUID
010df8cc-78c4-4349-9635-5d3f3b90eadb
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model

Literal federal measure citations: S. 839, H.R. 1492

HCR · Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.